# Genomic Characterization of Carbapenemases in Providencia Species from Croatia: The Results of the Multicenter Study

**Authors:** Jasmina Vraneš, Branka Bedenić, Gernot Zarfel, Josefa Luxner, Andrea Grisold, Rocio Arazo del Pino, Tessa Burgwinkel, Haris Car, Maja Anušić, Vladimira Tičić, Marina Bubonja-Šonje, Sanda Sardelić, Paul G. Higgins

PMC · DOI: 10.3390/genes17020203 · Genes · 2026-02-08

## TL;DR

This study analyzed carbapenem-resistant Providencia species in Croatia to understand their resistance mechanisms and spread.

## Contribution

The study provides the first genomic characterization of carbapenemases in Providencia species from Croatia.

## Key findings

- OXA-48 and NDM carbapenemases were identified in 15 isolates each.
- WGS revealed multiple resistance genes to various antibiotics, including aminoglycosides and tetracyclines.
- Isolates were categorized as extensively drug-resistant (XDR) with limited treatment options.

## Abstract

Background/objectives: A rise in infections associated with carbapenem-resistant Providencia species (CRPS) has been observed worldwide. This study presents a genomic analysis of CRPS isolates from four hospitals in Croatia and the outpatient setting, in order to determine the extent of the spread of CRPS in Croatia. In the present study, we applied a combination of phenotypic characterization and molecular analysis of resistance traits to determine the mechanisms and the routes of spread of CRPS. Material and methods: The antibiotic susceptibility testing was performed using disk-diffusion and broth dilution methods. The nature of extended-spectrum β-lactamases (ESBLs), carbapenemases, and fluoroquinolone resistance determinants was investigated by polymerase chain reaction (PCR). In order to obtain an insight into the whole resistome, selected isolates were subjected to the Interarray Genotyping Kit CarbaResist and whole genome sequencing (WGS). Results: In total, 30 isolates were collected from four centers, located in different geographic regions of Croatia. There was uniform resistance to piperacillin-tazobactam, cefuroxime, expanded-spectrum cephalosporins (ESCs), imipenem, ertapenem, meropenem, and ciprofloxacin. Immunochromatographic testing and PCR revealed OXA-48 and NDM carbapenemase in 15 isolates, respectively. Phenotypic tests for ESBLs were positive in all OXA-48 and one NDM-positive organism (16 isolates). The isolates were categorized as extensively drug-resistant (XDR). OXA-48-producing isolates were susceptible only to ceftazidime-avibactam, whereas NDM producers were susceptible to cefiderocol and, in the majority of cases, also to amikacin. WGS identified a plethora of genes encoding resistance to aminoglycosides, such as aadA1 and aadA2, (aph(3″)-Ib and aph(6)-Id, sulfonamides sul1 and sul2, trimethoprim dfrA1, dfrA10, and dfrA12, tetracyclines tet(A) and tet(B), and chloramphenicol catA3 and catA5. Conclusions: Providencia spp., in spite of being a rare pathogen, should be included in the surveillance studies across the medical centers in Croatia.

## Linked entities

- **Genes:** aadA1 (ANT(3'')-Ia family aminoglycoside nucleotidyltransferase AadA1) [NCBI Gene 58164744], aph(3'')-Ib (aminoglycoside O-phosphotransferase APH(3'')-Ib) [NCBI Gene 23448054], sul-1 (Putative extracellular sulfatase Sulf-1 homolog) [NCBI Gene 180619], sul-2 (Sulfatase N-terminal domain-containing protein) [NCBI Gene 179194], dfrA1 (trimethoprim-resistant dihydrofolate reductase DfrA1) [NCBI Gene 57334187], dfrA12 (trimethoprim-resistant dihydrofolate reductase DfrA12) [NCBI Gene 75204014], tet(A) (tetracycline efflux MFS transporter Tet(A)) [NCBI Gene 33941499], tetB (multifunctional tetracycline-metal/H+ antiporter and Na+(K+)/H+ antiporter) [NCBI Gene 937890], LOC110872272 (catalase-like) [NCBI Gene 110872272]
- **Chemicals:** piperacillin-tazobactam (PubChem CID 461573), cefuroxime (PubChem CID 5479529), imipenem (PubChem CID 104838), ertapenem (PubChem CID 150610), meropenem (PubChem CID 441130), ciprofloxacin (PubChem CID 2764), ceftazidime-avibactam (PubChem CID 90643431), cefiderocol (PubChem CID 77843966), amikacin (PubChem CID 37768), trimethoprim (PubChem CID 5578), chloramphenicol (PubChem CID 5959)

## Full-text entities

- **Genes:** aadA2 [NCBI Gene 13919588], AmpC [NCBI Gene 5850688], dfrA1 [NCBI Gene 13919579], ESBL [NCBI Gene 13906541], beta-LACTAMASE [NCBI Gene 18262323], aadA1 [NCBI Gene 13919580], sul1 [NCBI Gene 13919586], dfrA12 [NCBI Gene 13919589]
- **Diseases:** psychiatric (MESH:D001523), CRPS (MESH:D060467), skin and soft-tissue infections (MESH:D018461), injury to (MESH:D014947), ESBLs (MESH:C579922), NDM-1 (MESH:C538557), colonized (MESH:D003108), pyuria (MESH:D011776), bloodstream infection (MESH:D018805), cross (MESH:C537866), Infection (MESH:D007239), XDR (MESH:D054908), wound infections (MESH:D014946), UTI (MESH:D014552), KPC (MESH:C565455), death (MESH:D003643)
- **Chemicals:** biotin (MESH:D001710), gentamicin (MESH:D005839), tazobactam (MESH:D000078142), amoxicillin (MESH:D000658), ertapenem (MESH:D000077727), cephamycins (MESH:D002513), water (MESH:D014867), cloxacillin (MESH:D003023), sodium azide (MESH:D019810), CAZ (MESH:D002442), Carbapenems (MESH:D015780), levofloxacin (MESH:D064704), meropenem (MESH:D000077731), cefepime (MESH:D000077723), tetracyclines (MESH:D013754), cefiderocol (MESH:C000612166), NOR (MESH:D009643), ethidium bromide (MESH:D004996), EDTA (MESH:D004492), IMP (MESH:D007291), Sulfonamide (MESH:D013449), amoxicillin-clavulanate (MESH:D019980), agar (MESH:D000362), ciprofloxacin (MESH:D002939), tigecycline (MESH:D000078304), monobactams (MESH:D008997), cefoxitin (MESH:D002440), saline (MESH:D012965), aminoglycoside (MESH:D000617), FEP (MESH:D011138), beta-lactam (MESH:D047090), chloramphenicol (MESH:D002701), imipenem (MESH:D015378), clavulanic acid (MESH:D019818), sulphamethoxazole-trimethoprim (MESH:D015662), agarose (MESH:D012685), NDM (MESH:C052821), trimethoprim (MESH:D014295), cephalosporin (MESH:D002511), dUTP (MESH:C027078), piperacillin-tazobactam (MESH:D000077725), ceftriaxone (MESH:D002443), amikacin (MESH:D000583), fluoroquinolone (MESH:D024841), -lactamases (-), cefotaxime (MESH:D002439), SMX (MESH:D013420), ceftazidime-avibactam (MESH:C000595613), cefuroxime (MESH:D002444), tetracycline (MESH:D013752), cephalexin (MESH:D002506), sulbactam (MESH:D013407)
- **Species:** Meleagris gallopavo (common turkey, species) [taxon 9103], Enterobacterales (order) [taxon 91347], Providencia rettgeri (species) [taxon 587], Klebsiella pneumoniae (species) [taxon 573], Escherichia coli (E. coli, species) [taxon 562], Providencia stuartii (species) [taxon 588], Escherichia coli ATCC 25922 (strain) [taxon 1322345], Acinetobacter baumannii (species) [taxon 470], Homo sapiens (human, species) [taxon 9606], Proteus mirabilis (species) [taxon 584]
- **Mutations:** TAG-C-3, TTG-CGG  5

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940733/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12940733/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940733/full.md

---
Source: https://tomesphere.com/paper/PMC12940733